In this article

Check out the companies making headlines before the bell:

Turning Point Therapeutics (TPTX) – The biopharmaceutical company's shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in cancer treatments.

In this article